[The effectiveness of parodontax toothpaste in the complex treatment of chronic gingivitis]

Was to evaluate the clinical efficacy of parodontax Comprehensive Protection (GlaxoSmithKline, London, UK) toothpaste in the complex therapy of chronic gingivitis.

The study involved 119 volunteers; group 1 (n=59, age range 18 to 32 years) and group 2 (n=60, age range 20 to 35 years) with a diagnosis of chronic gingivitis (K05.1). The criterion for inclusion in the study was sulcus bleeding index (SBI) more than 1 point. Dental examination included SBI, papillary-marginal-alveolar index (PMA), and Green-Vermillion oral hygiene index (OHI-S). After determining the indices, all patients underwent professional oral hygiene and controlled tooth cleaning. Patients in group 1 (parodontax) were prescribed parodontax Comprehensive Protection toothpaste (GlaxoSmithKline, London, UK), patients in group 2 - a toothpaste that did not contain sodium bicarbonate. Repeated clinical examinations with the determination of the SBI, PMA, OHI-S were carried out after week 2 and 4.

After 4 weeks, SBI scores in group 1 were 63% lower than at baseline, and in group 2 - by 30%. PMA values at 4 weeks in group 1 were 58% and in group 2 30% lower, compared to baseline levels. The results of the analysis of the OHI-S index showed a statistically significant decrease in group 1 by 75%, while in group 2 by only 8% from the initial values. The difference in all index values between groups at 4 weeks of the study was statistically significant (p<0.05).

The use of parodontax Comprehensive Protection Toothpaste (GlaxoSmithKline, London, UK) has been shown to reduce the clinical signs of biofilm-associated gingivitis and effectively maintain optimal oral hygiene in patients.